RECOVER-SLEEP: Platform Protocol
NCT06404086 is a phase 2 interventional trial sponsored by Duke University. As of 21 Nov 2026, it is completed. It studies Melantonin Placebo, Melatonin, Modafinil, Modafinil Placebo and 2 more drugs in Hypersomnia, Long COVID and 2 more conditions. The registry lists an enrollment of 830 participants at 47 sites in 1 country. The registry lists a start date of 31 Jul 2024 and a primary completion date of 31 Dec 2025.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06404086 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Duke University |
| Enrollment | 830 |
| Registered sites | 47 |
| Countries | 1 |
| Conditions | Hypersomnia, Long COVID, Long COVID-19 and Sleep Disturbance |
| Drugs | Melantonin Placebo, Melatonin, Modafinil, Modafinil Placebo, Solriamfetol and Solriamfetol Placebo |
| Start | 31 Jul 2024 |
| Primary completion | 31 Dec 2025 |
| Study completion | 31 Dec 2025 |
| Last update posted | 22 Jan 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Christina Barkauskas, MD
Duke Clinical Research Institute
Study Chair - Susan Redline, MD MPH
Brigham and Women's Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Banner University Medical Center Phoenix
Phoenix
- the Southern Arizona Va Health Care System
Tucson
- University of Arizona Banner Medical Center
Tucson
- Stanford University
Palo Alto
- University of California San Francisco General Hospital
San Francisco
- University of Colorado Anschutz Medical Campus
Aurora
- Denver Health and Hospital Authority
Denver
- Howard University Hospital
Washington D.C.
- University of Florida College of Medicine Jacksonville
Jacksonville
- Lakeland Regional Medical Center
Lakeland
- Emory University
Atlanta
- Grady Memorial Hospital
Atlanta
- Morehouse School of Medicine
Atlanta
- Atlanta Va Medical Center
Decatur
- Emory Hope Clinic
Decatur
- Cook County Health Specialty Care Center
Chicago
- Northwestern Memorial Hospital
Chicago
- Rush University Medical Center
Chicago
- University of Illinois at Chicago
Chicago
- Northshore Medical Group
Evanston
- Saint Francis Medical Center
Peoria
- University of Kansas Medical Center
Kansas City
- University of Kentucky
Lexington
- Johns Hopkins Bayview Medical Center
Baltimore
- Jadestone Clinical Research, Llc
Silver Spring
- Beth Israel Deaconess Med. Ctr.
Boston
- Boston Medical Center
Boston
- Brigham and Womens Hospital
Boston
- Massachusetts General Hospital
Boston
- Tufts Medical Center
Boston
- University of Massachusetts Memorial Medical Center
Worcester
- Rutgers University - Robert Wood Johnson Medical School
New Brunswick
- University of New Mexico
Albuquerque
- Icahn School of Medicine at Mount Sinai
New York
- East Carolina University
Greenville
- University of Cincinnati Medical Center
Cincinnati
- University Hospitals of Cleveland Medical Center
Cleveland
- Oregon Health and Science University
Portland
- Southwest Family Medicine Associates
Dallas
- Houston Methodist Hospital
Houston
- New Dawn Wellness and Medical Research Center
Houston
- University of Texas Health Science Center at Houston
Houston
- University of Virginia Health System
Charlottesville
- Evergreen Hospital Medical Center
Kirkland
- University Physicians and Surgeons (dba Marshall Health)
Huntington
- West Virginia Clinical and Translational Science Institute
Morgantown
- Medical College of Wisconsin
Milwaukee
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06404086
Each answer restates registry values shown on this page.
What is NCT06404086?
NCT06404086 is a phase 2 interventional trial sponsored by Duke University. It studies Melantonin Placebo, Melatonin, Modafinil, Modafinil Placebo and 2 more drugs in Hypersomnia, Long COVID and 2 more conditions.
Who leads NCT06404086?
The registry names Christina Barkauskas, MD (study chair, Duke Clinical Research Institute) and Susan Redline, MD MPH (study chair, Brigham and Women's Hospital) as overall officials.
Where does NCT06404086 run?
The registry lists 47 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06404086 study?
The registered drug and biological interventions are Melantonin Placebo, Melatonin, Modafinil, Modafinil Placebo, Solriamfetol and Solriamfetol Placebo.
When did NCT06404086 end?
The registry lists a primary completion date of 31 Dec 2025 and a study completion date of 31 Dec 2025. The sponsor last updated the record on 22 Jan 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.